OptimizeRx Corporation

NasdaqCM:OPRX Stok Raporu

Piyasa değeri: US$127.0m

OptimizeRx Yönetim

Yönetim kriter kontrolleri 3/4

OptimizeRx CEO'su Steve Silvestro, Jan2025 tarihinde atandı, in görev süresi 1.33 yıldır. in toplam yıllık tazminatı $ 2.72M olup, şirket hissesi ve opsiyonları dahil olmak üzere 18.4% maaş ve 81.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.53% ine doğrudan sahiptir ve bu hisseler $ 679.23K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.1 yıl ve 8.2 yıldır.

Anahtar bilgiler

Steve Silvestro

İcra Kurulu Başkanı

US$2.7m

Toplam tazminat

CEO maaş yüzdesi18.40%
CEO görev süresi1.3yrs
CEO sahipliği0.5%
Yönetim ortalama görev süresi3.1yrs
Yönetim Kurulu ortalama görev süresi8.2yrs

Son yönetim güncellemeleri

Recent updates

OPRX: Share Repurchases And Margin Gains Will Support Future Upside Potential

The analyst price target for OptimizeRx has moved from $32 to $20 as analysts factor in softer 2026 revenue expectations, lower revenue growth assumptions, falling peer multiples, and a higher discount rate, partly offset by improved profit margin forecasts and support from the new $10m share repurchase authorization. Analyst Commentary Recent research updates show that while price targets on OptimizeRx have been reset lower, several bullish analysts still highlight positive angles around execution, profitability, and capital allocation.

OPRX: Profit Execution And US$10m Buybacks Will Support Future Upside

Analysts have trimmed the blended price target for OptimizeRx to $14.50, reflecting softer 2026 revenue expectations, reduced revenue visibility, and lower peer multiples, partially offset by improved profit forecasts and support from the new $10m share repurchase authorization. Analyst Commentary Street research on OptimizeRx has turned more cautious on the revenue outlook through 2026, but there is still a split between what bullish analysts focus on and what more bearish analysts are worried about.

OPRX: Profit Focus And Buybacks Will Support Future Share Upside

Analysts have lowered their average price targets for OptimizeRx into the low to mid teens in dollar terms, citing reduced 2026 revenue visibility, softer pharma marketing budgets, pressure from peer multiples, and a greater focus on profitability and share repurchases. Analyst Commentary Street research on OptimizeRx has converged around lower price targets but with different degrees of optimism on execution, growth prospects, and valuation.

OPRX: Margin Discipline And Buybacks Will Support Future Upside Potential

Analysts have reduced the fair value estimate for OptimizeRx from $24.33 to $14.50, citing lower revenue growth expectations, reduced revenue visibility into 2026, and lower peer P/E multiples. These factors are partly offset by firmer profit margin forecasts and buy ratings that remain in place across several firms.

OPRX: Expanded Point Of Care Network Will Support Further Upside

Analysts have fine tuned their OptimizeRx price target to $24.33. This reflects updated assumptions around the discount rate, long term revenue growth, profit margin and future P/E multiple.

OPRX: New Data Partnerships Will Support Long Term Earnings Power

Analysts now maintain their price target for OptimizeRx at $17.00, reflecting updated assumptions for discount rate, revenue growth, profit margin, and future P/E that they view as broadly offsetting each other. What's in the News Announced a data collaboration with Experian at CES 2026 to connect OptimizeRx Micro-Neighborhood audiences with Experian's identity graph for onboarding, curation, and measurement of consumer audiences at scale (Client Announcements).

OPRX: Q3 Outperformance And 2026 Guidance Will Strengthen Long Term Earnings Power

Analysts have lifted their average price targets on OptimizeRx into a US$21 to US$32 range, citing stronger than guided Q3 performance, improved visibility after 2024, and expectations for ongoing double digit growth with expanding margins. Analyst Commentary Street research after the Q3 report has centered on stronger than guided results and higher price targets, with analysts highlighting improved earnings and better visibility beyond 2024.

OPRX: Q3 Execution Rebound And 2026 Guidance Will Support Further Upside

Analysts have lifted their blended price targets on OptimizeRx to a range of US$21 to US$32, citing stronger than guided Q3 revenue and EPS, improved visibility after 2024 execution issues, and continuing momentum that supports expectations for double digit growth with expanding margins. Analyst Commentary Across the Street, bullish analysts are taking Q3 as a sign that OptimizeRx may be getting back on track after earlier execution issues, and they have shifted their valuation ranges higher as a result.

OPRX: Higher Guidance And Margin Expansion Will Reshape Long Term Earnings Power

Analysts have lifted their fair value estimate for OptimizeRx from US$11.00 to US$17.00, reflecting higher price targets supported by recent revenue and EPS outperformance, improved growth visibility, and expectations for margin expansion. Analyst Commentary Street research on OptimizeRx has been broadly positive around the latest quarter, with several firms raising their price targets after revenue and EPS outperformance and clearer guidance.

OPRX Will Extend Double Digit Revenue Trajectory With New Multi Year Partnerships

Analysts have lifted their price target on OptimizeRx by $5 to $32 per share, citing consistently strong quarterly outperformance, improving visibility after last year's weak execution, and a more durable outlook for double digit revenue growth and expanding margins. Analyst Commentary Bullish analysts are increasingly aligned around a constructive view of OptimizeRx, pointing to a series of price target hikes following its latest quarterly results.

OPRX: Recurring Revenue Shift And 2026 Guidance Will Drive Future Upside

Analysts have nudged their price targets on OptimizeRx higher, with recent increases across the Street ranging from about $1 to $10 per share to reflect stronger than expected Q3 revenue and EPS, improved visibility, and confidence in sustained double digit growth and margin expansion. Analyst Commentary Bullish analysts highlighted that the latest quarter materially exceeded revenue expectations, driving meaningful EPS upside and reinforcing confidence in a durable, double digit growth profile.

OPRX: Multi-Year Guidance and Recurring Revenue Will Drive Upside Momentum

OptimizeRx's analyst price target has increased from $22 to approximately $24.33 per share. This reflects ongoing revenue outperformance and improved visibility that analysts attribute to strong quarterly results and the company's growing momentum.

OptimizeRx Corporation's (NASDAQ:OPRX) 33% Share Price Plunge Could Signal Some Risk

Nov 23
OptimizeRx Corporation's (NASDAQ:OPRX) 33% Share Price Plunge Could Signal Some Risk

OPRX: Expanding Margins and Subscription Model Will Drive Shareholder Value Forward

OptimizeRx's analyst fair value target has been raised from $19 to $22.00 per share. This change reflects stronger quarterly results, improved growth prospects, and expanding profit margins, according to analysts.

Is OptimizeRx (NASDAQ:OPRX) Using Too Much Debt?

Oct 07
Is OptimizeRx (NASDAQ:OPRX) Using Too Much Debt?

Are Investors Undervaluing OptimizeRx Corporation (NASDAQ:OPRX) By 39%?

Aug 27
Are Investors Undervaluing OptimizeRx Corporation (NASDAQ:OPRX) By 39%?

Pharmaceutical Digital Engagement Will Unlock Future Value

Despite near-term cautious revenue guidance, analysts remain optimistic on OptimizeRx due to Q2 earnings outperformance, improved management transparency, and ongoing strategic initiatives, maintaining the consensus price target at $19.00. Analyst Commentary Bullish analysts highlight OptimizeRx’s Q2 revenues and adjusted EBITDA significantly surpassing forecasts.

Even With A 33% Surge, Cautious Investors Are Not Rewarding OptimizeRx Corporation's (NASDAQ:OPRX) Performance Completely

May 09
Even With A 33% Surge, Cautious Investors Are Not Rewarding OptimizeRx Corporation's (NASDAQ:OPRX) Performance Completely
User avatar

A Subscription Model And EHR Network Will Reshape Healthcare

Transitioning to a subscription-based model aims to enhance revenue predictability and improve net margins with recurring income.

Is OptimizeRx Corporation (NASDAQ:OPRX) Expensive For A Reason? A Look At Its Intrinsic Value

Apr 06
Is OptimizeRx Corporation (NASDAQ:OPRX) Expensive For A Reason? A Look At Its Intrinsic Value

We Think OptimizeRx (NASDAQ:OPRX) Has A Fair Chunk Of Debt

Mar 08
We Think OptimizeRx (NASDAQ:OPRX) Has A Fair Chunk Of Debt

At US$6.29, Is It Time To Put OptimizeRx Corporation (NASDAQ:OPRX) On Your Watch List?

Feb 14
At US$6.29, Is It Time To Put OptimizeRx Corporation (NASDAQ:OPRX) On Your Watch List?

Market Might Still Lack Some Conviction On OptimizeRx Corporation (NASDAQ:OPRX) Even After 30% Share Price Boost

Dec 15
Market Might Still Lack Some Conviction On OptimizeRx Corporation (NASDAQ:OPRX) Even After 30% Share Price Boost

Does OptimizeRx (NASDAQ:OPRX) Have A Healthy Balance Sheet?

Nov 16
Does OptimizeRx (NASDAQ:OPRX) Have A Healthy Balance Sheet?

OptimizeRx (NASDAQ:OPRX) Is Carrying A Fair Bit Of Debt

Jul 30
OptimizeRx (NASDAQ:OPRX) Is Carrying A Fair Bit Of Debt

OptimizeRx Corporation's (NASDAQ:OPRX) 36% Jump Shows Its Popularity With Investors

Jan 09
OptimizeRx Corporation's (NASDAQ:OPRX) 36% Jump Shows Its Popularity With Investors

CEO Tazminat Analizi

Steve Silvestro'un ücretlendirmesi OptimizeRx'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Dec 31 2025US$3mUS$500k

US$5m

Sep 30 2025n/an/a

US$34k

Jun 30 2025n/an/a

-US$10m

Mar 31 2025n/an/a

-US$15m

Dec 31 2024US$973kUS$400k

-US$20m

Sep 30 2024n/an/a

-US$24m

Jun 30 2024n/an/a

-US$18m

Mar 31 2024n/an/a

-US$18m

Dec 31 2023US$970kUS$385k

-US$18m

Sep 30 2023n/an/a

-US$14m

Jun 30 2023n/an/a

-US$14m

Mar 31 2023n/an/a

-US$14m

Dec 31 2022US$2mUS$330k

-US$11m

Sep 30 2022n/an/a

-US$10m

Jun 30 2022n/an/a

-US$7m

Mar 31 2022n/an/a

-US$3m

Dec 31 2021US$1mUS$330k

US$378k

Sep 30 2021n/an/a

US$1m

Jun 30 2021n/an/a

US$789k

Mar 31 2021n/an/a

-US$641k

Dec 31 2020US$866kUS$300k

-US$2m

Sep 30 2020n/an/a

-US$6m

Jun 30 2020n/an/a

-US$7m

Mar 31 2020n/an/a

-US$5m

Dec 31 2019US$1mUS$189k

-US$3m

Tazminat ve Piyasa: Steve 'nin toplam tazminatı ($USD 2.72M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 618.00K ).

Tazminat ve Kazançlar: Steve 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Steve Silvestro (47 yo)

1.3yrs
Görev süresi
US$2,717,717
Tazminat

Mr. Stephen L. Silvestro, also known as Steve, has been the Chief Executive Officer of OptimizeRx Corporation since January 2025 and its Director since June 2025. He served as President at OptimizeRx Corp....

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Stephen Silvestro
CEO & Director1.3yrsUS$2.72m0.53%
$ 679.2k
Edward Stelmakh
Chief Financial & Strategic Officer4.6yrsUS$1.52m0.43%
$ 541.2k
Theresa Greco
Chief Commercial Officer2.6yrsUS$1.54m0.17%
$ 211.5k
Brendan Merrell
Chief Operating Officerless than a yearVeri yok0.053%
$ 67.4k
Marion Odence-Ford
Chief Legal & Administrative Officer5.3yrsUS$2.51m0.26%
$ 329.7k
Maira Alejandra
Media Relations Managerno dataVeri yokVeri yok
Andrew D'Silva
Chief Business Officerless than a yearVeri yok0.11%
$ 143.5k
Doug Besch
Chief Product Officer & CTO3.6yrsVeri yok0.13%
$ 160.1k
Heather Favazza
Controller7.6yrsVeri yokVeri yok
Sheryl Kearney
Human Resources Managerno dataVeri yokVeri yok
3.1yrs
Ortalama Görev Süresi
47yo
Ortalama Yaş

Deneyimli Yönetim: OPRX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.1 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Patrick Spangler
Independent Director8.2yrsUS$234.99k0.18%
$ 232.5k
Catherine Klema
Independent Director2.3yrsUS$227.99k0.063%
$ 79.6k
Gregory Wasson
Independent Director5.8yrsUS$200.99k0.25%
$ 320.3k
Ellen Vos
Independent Chairperson of the Board10.7yrsUS$268.99k0.33%
$ 425.0k
Jack Pinney
Head of Medical Advisory Board8.2yrsUS$112.91kVeri yok
James Lang
Independent Director9.3yrsUS$203.99k2.08%
$ 2.6m
Mary Presti
Independent Directorless than a yearVeri yokVeri yok
8.2yrs
Ortalama Görev Süresi
67yo
Ortalama Yaş

Deneyimli Yönetim Kurulu: OPRX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.2 yıldır).

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/05 21:55
Gün Sonu Hisse Fiyatı2026/05/05 00:00
Kazançlar2025/12/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

OptimizeRx Corporation 12 Bu analistlerden 7, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Anderson SchockB. Riley Securities, Inc.
Constantine DavidesCitizens JMP Securities, LLC
Eric MartinuzziLake Street Capital Markets, LLC